1. Home /
    2. Altai Protocol Library /
  2. New Indication: Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Indication: Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer

New Indication: Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer
Study:
  • Randomized, two-group, open- label, phase 3 trial
  • HER2- low, unresectable or metastatic breast cancer
  • One or two previous lines of chemotherapy
  • Trastuzumab deruxtecan (N:373) or the physician’s choice of chemotherapy (N:184)
  • HER2 low disease: IHC 1+ or IHC 2+ and negative in situ hybridization.
Efficacy:
  • mPFS: 9.9 m vs 5.1 m (HR:0.50; P<0.001)
  • mOS: 23.4 m vs 16.8 m (HR: 0.64; P=0.001)
Safety:
  • Grade >= 3 AEs: 52.6% vs 67.4%
  • Drug related interstitial lung disease or pneumonitis: 12.1% for trastuzumab deruxtecan, 0.8% had grade 5 events.

N Engl J Med 2022 Jun 5. doi: 10.1056/NEJMoa2203690.

Modi, Shanu et al. “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.”

https://doi.org/10.1056/nejmoa2203690

Reviewed by Hasan Çağrı Yıldırım, MD on Jul 05, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More